Lunai Bioworks Inc. Cash Flow Conversion Efficiency
Lunai Bioworks Inc. cash flow conversion efficiency. Based on the latest financial reports, Lunai Bioworks Inc. (LNAI) has a cash flow conversion efficiency ratio of 0.107x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.03 Million) by net assets ($-9.55 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Lunai Bioworks Inc. (2021–2025)
Cash flow conversion efficiency of Lunai Bioworks Inc. from 2021 to 2025. This chart illustrates how Lunai Bioworks Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View Lunai Bioworks Inc. (LNAI) stock price for real-time trading data and today's change.
Lunai Bioworks Inc. Cash Flow Conversion Ratio Explained
Lunai Bioworks Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Lunai Bioworks Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lunai Bioworks Inc. ranked by their cash flow conversion efficiency. Also see how much is Lunai Bioworks Inc. worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Frenkel Topping Group
LSE:FEN
|
0.040x |
|
Hanstone Gold Corp
V:HANS
|
0.486x |
|
BLUEBIRD MERCH.VENT. LTD.
F:09D
|
N/A |
|
Enveric Biosciences Inc
NASDAQ:ENVB
|
-0.600x |
|
Norrland Gold Corp
V:NORR
|
-0.074x |
|
National World PLC
LSE:NWOR
|
0.024x |
|
REVITALIST L.A.W. LTD
F:4DO
|
N/A |
|
Brain+ ApS
CO:BRAINP
|
-0.964x |
Annual Cash Flow Conversion Efficiency for Lunai Bioworks Inc. (2021–2025)
The table below shows the annual cash flow conversion efficiency of Lunai Bioworks Inc. from 2021 to 2025. Review LNAI financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $-21.35 Million | $-7.87 Million | 0.369x | +543.68% |
| 2024-06-30 | $131.98 Million | $-10.97 Million | -0.083x | +67.17% |
| 2023-06-30 | $46.50 Million | $-11.77 Million | -0.253x | -16.88% |
| 2022-06-30 | $72.62 Million | $-15.73 Million | -0.217x | -83.59% |
| 2021-06-30 | $174.66 Million | $-20.61 Million | -0.118x | -- |
About Lunai Bioworks Inc.
Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands. It operates through three segments, RENB, BioSymetrics, and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; a… Read more